Gratiago

Gratiago is a European digital health start-up dedicated to improving treatment adherence, persistence and patient engagement in chronic and complex diseases, including oncology and immunology, where non-adherence remains a major driver of poor outcomes, reduced quality of life and inefficiencies in healthcare systems.

Many patients undergoing long-term or intensive treatments discontinue or irregularly follow their therapy despite clear clinical benefit. This challenge is particularly acute in oncology, where oral and long-term treatments place a significant behavioural, emotional and cognitive burden on patients, directly impacting treatment effectiveness, survival and quality of life.

Gratiago develops patient-centred digital therapeutics that combine behavioural science, motivational mechanisms and AI-driven personalisation to support patients throughout their treatment journey. The platform delivers adaptive reminders, encouragements and contextualised interactions aligned with individual profiles, disease characteristics and treatment phases. Its objective is to sustain long-term engagement, strengthen persistence and support patients in remaining on effective therapies over time.

The solution is currently undergoing clinical validation in collaboration with hospital partners and has been designed to generate robust real-world evidence on patient engagement, adherence and behavioural patterns. Gratiago integrates patient-reported outcomes (PROMs), patient-reported experience measures (PREMs) and behavioural data to support clinicians, researchers and healthcare stakeholders with actionable insights derived from real-life use.

Gratiago’s technology is conceived as a modular, interoperable and regulation-aware digital component that can be integrated into existing care pathways, digital therapeutics ecosystems and pharmaceutical “beyond-the-pill” strategies. It supports multi-stakeholder collaboration between patients, care teams, researchers and industry partners.

Within Horizon Europe and EU Mission Cancer projects, Gratiago contributes as an SME partner by providing:

• a clinically grounded digital therapeutic targeting treatment adherence and persistence,

• expertise in patient-centred and behaviour-driven digital intervention design,

• capabilities to collect, analyse and valorise behavioural and engagement-related real-world data,

• experience in clinical pilots, regulatory-aware development and stakeholder co-creation.

Gratiago is particularly interested in participating in consortia addressing oncology and other chronic non-communicable diseases, patient quality of life, digital health innovations, behavioural and supportive care interventions, and the generation of clinical and real-world evidence supporting personalised, equitable and sustainable healthcare models.